GlassScriptPhysician profile
Zheng Wu
NPI 1780830679
$3,519.24
in general payments reported to CMS, 2019-2025
14 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $78.49 · 2021: $11.92 · 2022: $179 · 2023: $278 · 2024: $806 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906 · Travel and Lodging: $1,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.46 |
| Travel and Lodging | $1,343.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,678.78 | 2025 | |
| Janssen Biotech, INC. | $297.13 | 2020-2025 | Carvykti, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $295.60 | 2020-2023 | Opdivo, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $235.88 | 2024-2025 | Enhertu |
| Tempus Ai, INC | $182.25 | 2024-2025 | Xt Cdx |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Eisai INC. | $124.64 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $124.64 | 2024 | Libtayo |
| Genentech USA, INC. | $117.94 | 2024 | Lunsumio |
| Genmab U.S., INC. | $104.83 | 2024 | Epkinly |
| Genzyme Corporation | $96.02 | 2022 | |
| Pfizer INC. | $82.53 | 2022 | |
| Abbvie INC. | $34.95 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zheng Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.